|
FY2017
12 months to Dec 31, 2017
|
|
|---|---|
| Cash flows from operating activities: | |
| Net income | |
| Adjustments to reconcile net income to net cash flows from operating activities: | |
| Depreciation and amortization | |
| Stock-based compensation | |
| Deferred taxes | |
| Remeasurement of contingent consideration | |
| Changes in operating assets and liabilities, net: | |
| Accounts receivable | |
| Inventory | |
| Due from Biogen, net | |
| Other assets | |
| Accounts payable | |
| Accrued expenses and other current liabilities | |
| Other liabilities | |
| Net cash flows provided by operating activities | |
| Cash flows from investing activities: | |
| Purchases of property, plant and equipment | |
| Acquisition of True North Therapeutics, net of cash | |
| Net cash flows used in investing activities | |
| Cash flows from financing activities: | |
| Transfers to Biogen | |
| Cash from Biogen upon separation | |
| Working capital adjustments paid to Biogen, net | |
| Shares issued under employee benefit plans | |
| Net cash flows provided by (used in) financing activities | |
| Effect of foreign exchange rate changes on cash and equivalents | |
| Net increase in cash and cash equivalents | |
| Cash and cash equivalents, end of the year | |
| Supplemental cash flow disclosure: | |
| Cash paid for income taxes |
Loading...
